CellFE and Made Scientific Partner to Advance Non-Viral Gene Editing in T Cell Therapies
Wednesday, May 14, 2025
CellFE, a specialist in microfluidics-based cell engineering, has entered a strategic collaboration with Made Scientific, a contract development and manufacturing organisation (CDMO) focused on cell therapies. The partnership aims to generate pilot data using CellFE’s High Volume Cyva™ System and assess its clinical-scale capabilities for non-viral gene editing in both activated and resting T cell therapies.
The pilot study will examine two manufacturing processes. The first involves activated T cells and combines non-viral and viral gene editing methods to quickly produce autologous T cell products, meeting growing demand for personalised immunotherapies. The second will focus on quiescent or resting T cells, aiming to demonstrate the feasibility of an allogeneic, off-the-shelf approach that could improve patient access and reduce treatment timelines.
CellFE has chosen Made Scientific to carry out pilot-scale trials of the High Volume Cyva™ System, taking advantage of Made’s advanced manufacturing infrastructure and expertise in cell therapy process development. The collaboration will assess the scalability and performance of CellFE’s microfluidics platform, which is designed to preserve cell health, enhance yields, and support complex genome editing without relying on viral vectors.
This approach is intended to address key industry challenges, including scalability, production costs, and time-to-market, ultimately helping to accelerate the delivery of advanced cell therapies.
The partnership is expected to deliver valuable data supporting the clinical application of CellFE’s technology and help set new standards in T cell therapy manufacturing.
Source: prnewswire.com
